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doi:10.1016/j.pedneo.2011.11.003Kawasaki disease (KD) is an acute multi-system vasculitis syndrome of unknown etiology occur-
ring mostly in infants and children younger than 5 years of age. In developed countries, it is the
leading cause of acquired heart disease in children. However, KD remains a mysterious disease.
Some viruses potentially causing the condition have been isolated, but the results have not
been able to be reproduced. This article reviews and summarizes different aspects of KD
and provides updated information on diagnosis and treatment. The supplementary criteria
for incomplete presentation of KD patients suggested by the American Heart Association,
treatment (including tumor necrosis factor-alpha antagonist, methylprednisolone pulse
therapy, statins, plasma exchange, and cytotoxic agents) for those with intravenous immuno-
globulin treatment failure, and other experiences are also included in this review.
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Kawasaki disease (KD) is an acute febrile systemic vasculitis
that was first described by Kawasaki et al1 in 1974. In
developed countries, it is the leading cause of acquired
heart disease in children, however its etiology remainsed by Elsevier Taiwan LLC. All rights reserved.
Updates of Kawasaki disease 5unknown.2e4 KD mainly affects children less than 5 years of
age, especially those in Asian countries, but its incidence
has increased worldwide. In Japan, Korea, and Taiwan, the
incidence ranges from 69 to 218 cases per 100,000 children
less than 5 years of age.5e7 The incidence of KD in Taiwan
has increased from 66 to 69 per 100,000 children aged less
than 5 years.5e8 An epidemiologic survey of KD in Taiwan
from 2003 to 2006 found that 1.5% of all cases were
recurrent.6 In Taiwan, KD occurs most frequently in the
summer (April to June) and least frequently in the winter,
but for unknown reasons, its seasonal occurrence varies in
other countries. The most serious complication of KD is the
involvement of coronary artery lesions (CAL), including
myocardial infarction, coronary artery fistula formation,9
coronary artery dilatation, and coronary artery aneurysm.10
The most commonly used definition of CAL (also known
as coronary artery abnormality, CAA, or CALs) is based on
the Japanese Ministry of Health criteria: maximum absolute
internal diameter >3 mm in children younger than 5 years
of age or >4 mm in children 5 years and older, or
a segmental diameter 1.5 times greater than that of an
adjacent segment, or the presence of luminal irregu-
larity.11e15 Coronary arteries should be corrected relative
to body surface area (if available) and expressed as stan-
dard deviation units from the mean (Z scores).16 Several
studies have analyzed CAL, including aortic root dimen-
sion,17 and transient CAL (the definition of “transient”
varies among studies, from 30 days to 6e8 weeks after
diagnosis of disease). As such, KD patients with coronary
artery ectasia or dilatation, which disappears within the
first 8 weeks after disease onset, are defined as transient
ectasia or dilatation (transient CAL). According to our
previous report on CAL analysis including 341 KD patients,18
35% of KD patients had dilatation during the acute phase of
admission, 17.2% had dilatation 1 month after disease
onset, 10.2% had dilatation at 2 months, and 4% had
persistent CAL for more than 1 year.19
Although the clinical features of KD are recognizable, its
underlying immunopathogenetic mechanisms are still under
investigation, particularly the agent responsible for the
development of CAL. KD is regarded as an autoimmune
disorder rather than an infectious disease.17 Kuo et al20
reported that persistent monocytosis after intravenous
immunoglobulin (IVIG) treatment is associated with CAL
formation. Eosinophils were also higher in KD patients than
in age-matched febrile controls. In addition, IVIG treatment
significantly increased eosinophils in KD patients. This
increase of eosinophils after IVIG treatment is inversely
correlated with IVIG treatment failure in KD.21 Further
studies have shown that changes of eosinophils after IVIG
treatment were positively correlated with changes in
interleukin (IL)-5 levels. An increase in eosinophils and IL-5
levels after IVIG treatment was inversely correlated with
CAL formation.22
Immune- and apoptosis-related genes [cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4), caspase 3
(CASP3), IL-10, IL-1B, CD40L, programmed death 1 (PD-1),
ORAI1, and inositol 1,4,5-trisphosphate 3-kinase C (ITPKC)]
have been associated with susceptibility and/or disease
outcome,13,15,18,19,22e30 further highlighting the involve-
ment of immune responses and imbalances between T
helper cell 1/2 (Th1/Th2) immune responses in thepathogenesis of KD. A skewed Th2 response (eosinophil and
IL-5 levels) may indicate good IVIG treatment response and
subsequent disease outcome. Weng et al26 reported that an
IL-10 gene polymorphism is associated with CAL formation
and IL-1B is associated with IVIG treatment response.25
Some studies of genetic variants also found a difference
between male and female genders, including CTLA-4 and
cytokine genes (IL-1B, IL-4, IL-8, and IL-10).30,31 Shimizu
et al17 reported that the transforming growth factor-beta
(TGF-b) signaling pathway influences KD susceptibility,
disease outcome, and the response to IVIG therapy, and
also shows immune response dysregulation. The inheritance
patterns of these traits have not been described in these
studies. It is likely that multiple polymorphic alleles influ-
ence KD susceptibility and disease outcome. This suggests
that different ethnic populations and different genders may
have different susceptibilities to KD.
The diagnosis and treatment of KD has become one of
the most controversial issues for pediatricians in Taiwan,
based on a nationwide questionnaire conducted by the
Taiwan Pediatric Association in 2009. This article reviews
updated information on KD and focuses on diagnosis and
treatment aspects of the disease.2. Updates on the Diagnosis of Kawasaki
Disease
The clinical characteristics of KD patients include prolonged
fever lasting longer than 5 days, diffuse mucosal inflamma-
tion, bilateral nonpurulent conjunctivitis, dysmorphic skin
rashes, indurative angioedema over the hands and feet, and
cervical lymphadenopathy. In addition to the diagnostic
criteria, there is a broad range of nonspecific clinical
features, including irritability, uveitis, aseptic meningitis,
cough, vomiting, diarrhea, abdominal pain, gallbladder
hydrops, urethritis, arthralgia, arthritis, hypoalbuminemia,4
liver function impairment, and heart failure.3,21,32
To date, there is no specific diagnostic test for KD.
Diagnosis is based on the presence of fever lasting longer
than 5 days and four of five specific clinical criteria. In
Japan, at least five of six criteria (fever and five other
clinical criteria) should be fulfilled for a diagnosis of KD.
However, patients with four of the principal clinical
features can be diagnosed when coronary aneurysm or
dilatation is recognized.24 From the Japanese Circulation
Society Joint Working Groups criteria (JCS 2008, Guidelines
for diagnosis and management of cardiovascular sequelae
in Kawasaki disease),33 KD can be diagnosed even when
fever lasts less than 5 days. However, according to the
American Heart Association (AHA) criteria,10 fever lasting
more than 5 days is essential for KD diagnosis (comparison
of diagnosis criteria from JCS and AHA is shown in Table 1).
Some patients who do not fulfill the criteria outlined in
Table 1 have been diagnosed with “incomplete” or “atyp-
ical” KD, a diagnosis often based on echocardiographic
identification of CAL. The term “incomplete” may be
preferable to “atypical” because these patients have
insufficient criteria instead of atypical presentation.10
In countries with a bacillus Calmette-Gue´rin (BCG)
vaccine policy (i.e., Taiwan and Japan), KD with erythem-
atous induration or even ulceration of the BCG scars has
Table 1 Comparison of the diagnostic criteria of Kawasaki disease.
AHA criteria 2004 JCS 2008 Guidelines
Fever 5 days and at least 4 of the following 5 At least 5 of the following 6
Bilateral nonsuppurative conjunctivitis The same
One or more changes to the mucous membranes including pharyngeal injection,
dry fissured lips, injected lips, and strawberry tongue
The same
Indurative angioedema of the hands and feet including peripheral erythema,
peripheral edema, periungual desquamation, and generalized desquamation
The same
Dysmorphous skin rashes The same
Acute nonpurulent cervical lymphadenopathy >1.5 cm in diameter The same
Fever*
*Fever of more than 5 days is essential for diagnosis in AHA (American Heart Association) 2004 criteria but not in the JCS (Japanese
Circulation Society) 2008 criteria.
Table 2 Supplementary laboratory criteria for incomplete
Kawasaki disease.
Fever of >5 d associated with 2 or 3 clinical criteria,
C-reactive protein 3.0 mg/dL and/or erythrocyte
sedimentation rate 40 mm/h with the following criteria
(1) albumin  3.0 g/dL
(2) anemia for age
(3) elevation of alanine aminotransferase
(4) platelets after 7 d  450,000/mm3
(5) white blood cell count 15,000/mm3
(6) urine 10 white blood cells/high-power field
Modified from Newburger et al.10
If 3 supplement criteria are met, intravenous immunoglobulin
can be prescribed before performing echocardiography.
CRP Z C-reactive protein; ESR Z erythrocyte sedimentation
rate; IVIG Z intravenous immunoglobulin.
6 H.-C. Kuo et albeen observed in one-third to half of KD patients (the
incidence of BCG site induration is higher than that of neck
lymphadenopathy in these countries).2 Uehara et al34 re-
ported that redness or the formation of a crust at the BCG
inoculation site is a useful diagnostic sign for KD in children
aged 3e20 months. Even if patients have four or fewer signs
of the clinical criteria for KD, physicians should consider
the redness or crust formation at the BCG inoculation site
as a possible indicator of KD.
Atypical cases of KD are not uncommon (up to 15e20%).
The incidence of CAL in patients exhibiting four principal
symptoms of KD is slightly higher than in patients with five
to six principal symptoms.35 Presentation of a small number
(< 4) of principal symptoms does not indicate a milder form
of the disease. Patients with at least four principal symp-
toms require the same treatment as patients with complete
(typical) KD, and those with three or fewer principal
symptoms should be treated similarly when they meet the
supplementary criteria. Herein, common supplementary
criteria for the diagnosis of incomplete KD are introduced.
3. American Heart Association (AHA)
Criteria 2004
Incomplete KD is more common in young infants than in
older children, making accurate diagnosis and timely
treatment especially important in these young patients who
are at substantial risk of developing coronary abnormali-
ties.36,37 The incidence of KD is actually higher than
previously reported throughout the world, partly because
earlier reports did not take incomplete forms into account.
The AHA criteria (2004), which incorporate suggestions for
laboratory tests and early echocardiography, are helpful for
diagnosing incomplete KD.32,38 Consultation with an expert
(cardiologist, immunologist, or rheumatologist) should be
sought at any time when assistance in making a diagnosis is
needed. Patients with fever for  five days (with 2 or 3
principal clinical features for KD) without other explanation
should undergo laboratory testing, and if there is evidence
of systemic inflammation, an echocardiogram should be
obtained even if the patient does not fully meet the clinical
criteria for KD. Infants 6 months old with fever for 7
days without other explanation should undergo laboratory
testing, and if evidence of systemic inflammation is found,an echocardiogram should be obtained even if the infant
has no clinical criteria for KD.10
The 2004 AHA supplemental laboratory criteria (Table 2)
include: (1) albumin 3.0 g/dL; (2) anemia for age; (3)
elevation of alanine aminotransferase; (4) platelets after 7
days 450,000/mm3; (5) white blood cell count 15,000/
mm3; and (6) urine 10 white blood cells/high-power
field.10 If a patient has more than three supplementary
criteria, incomplete KD is diagnosed and IVIG should be
prescribed before performing echocardiography.10
4. Updates on the Treatment of Kawasaki
Disease
4.1. Aspirin
Aspirin has been used in the treatment of KD for many
years, even before the advent of IVIG. Although aspirin has
important anti-inflammatory (high-dose) and antiplatelet
(low-dose) activity, it does not appear to lower the
frequency of CAL formation. During the acute phase of the
illness, aspirin is administered at 80 to 100 mg/kg per day
(30e50 mg/kg in Japan)39 in four doses with IVIG. High-
dose aspirin and IVIG appear to possess additive anti-
inflammatory effects.
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administration vary across countries and centers, many of
which reduce the aspirin dose when the patient is afebrile.
When high-dose aspirin is discontinued, low-dose aspirin
(3e5 mg/kg/day) is given until there is no evidence of CAL
and inflammatory markers [including platelets, C-reactive
protein (CRP), and erythrocyte sedimentation rate (ESR)]
have returned to normal levels, which usually occurs 6e8
weeks after disease onset. For children who develop CAL,
low-dose aspirin (or other antiplatelet agents) is continued
indefinitely until the inflammatory markers return to the
normal range and the echocardiogram does not show
abnormalities. Hsieh et al39 reported that regardless of
timing (before or after Day 5 of the illness), single-infusion,
high-dose (2 g/kg) aspirin in the acute stage of KD had no
effect on the response rate to IVIG therapy, duration of
fever, or the incidence of CAL. This review reiterates the
recommendation that exposing children to high-dose
aspirin therapy in the acute phase of KD is unnecessary
because available data show no appreciable benefit to IVIG
therapy response, CAL formation, or fever duration.
Our recent study investigated 609 KD patients from two
medical centers in Taiwan.40 The patients were divided into
Group 1, with high-dose aspirin (n Z 274), and Group 2,
without high-dose aspirin (n Z 335). There were no
significant differences between groups 1 and 2 in terms of
gender (pZ 0.51), IVIG resistance rate (34/274 vs. 26/335,
p Z 0.06), CAL formation rate (57/274 vs. 74/335,
p Z 0.64), and total hospital stay (6.3  0.2 vs. 6.7  0.2,
p Z 0.13). There were also no significant differences
between total white blood counts, hemoglobin levels,
platelet counts, and CRP levels before (within 1 day) and
after (within 3 days) IVIG treatment between the two
groups (p > 0.1). These results provide evidence that high-
dose aspirin in the acute phase of KD does not affect the
treatment results (CAL and IVIG resistance rate) or
inflammatory condition. High-dose aspirin treatment in the
acute phase of KD seems to be unnecessary and further
randomized controlled trials are needed.4.2. Intravenous immunoglobulin (IVIG)
responsiveness
The efficacy of IVIG administered in the acute phase of KD
for reducing the incidence of coronary artery abnormalities
is well established.41 The mechanism of IVIG action is still
under investigation. IVIG appears to have a generalized
anti-inflammatory effect. Possible mechanisms of action
include modulation of cytokine production, neutralization
of bacterial super-antigens or other etiologic agents,
augmentation of regulatory T cell activity (TGF-b),17
suppression of antibody synthesis and inflammatory
markers (CD40L, nitric oxide, and iNOS expression),42,43
providing of anti-idiotypic antibodies, and balancing Th1/
Th2 responses.20e22
KD patients should be treated with a single 12-hour
infusion of IVIG, 2 g/kg in a single infusion, together with
aspirin in acute phase with fever, or inflammation
progression without fever.2,3,10 This therapy should be
performed within 10 days of illness onset, and if this is not
possible, within 7 days of illness onset. Treatment of KDbefore Day 5 of the illness appears no more likely to
prevent cardiac sequelae than treatment on Days 5e9. It
may, however, be associated with an increased need for
IVIG retreatment.44,45 In the presence of four of five classic
criteria for KD, US and Japanese experts agree that only 4
days of fever are necessary before initiating treatment with
IVIG.10,46
The efficacy of treating patients using IVIG after 10 days
of illness is unknown; therefore, early diagnosis and
treatment is desired. IVIG should be administered to chil-
dren presenting after Day 10 of illness (i.e., children with
delayed diagnosis or incomplete KD) if they have either
persistent fever without explanation or aneurysms and
ongoing systemic inflammation, as manifested by elevated
ESR or CRP.3,47e49 Burns et al3 also suggested that any child
with KD who has evidence of persisting inflammation,
including fever or high concentrations of inflammatory
markers with or without coronary artery abnormalities,
should be treated even if the diagnosis is made after 10
days of illness.
4.3. IVIG resistance (initial IVIG treatment failure)
The incidence of IVIG resistance varies between centers,
from 9.4% to 23% (but it can be as high as 38%, as reported
in one American cohort).50 Recent studies have identified
demographic and laboratory characteristics as predictors of
IVIG resistance, including age, illness day, platelet count,
ESR, hemoglobin concentration, CRP, eosinophil, lactate
dehydrogenase, albumin, and alanine aminotransferase
(ALT).4,21,51e53 Because IVIG-resistant patients are at
a higher risk for CAL formation, it is important to identify
those who may benefit from a more aggressive therapy. As
shown in Figure 1 (modified from Newburger et al10), there
are no definite treatment principles available for the
management of KD patients with initial IVIG resistance or
unresponsiveness to other adjuvant therapies. A second
dose of IVIG (1 g/kg or 2 g/kg),10,54 methylprednisolone
pulse therapy,55 tumor necrosis factor-alpha (TNF-a)
blockade,56 cytotoxic agents (cyclophosphoamide, cyclo-
sporine A, or MTX57), plasmapheresis,58 and plasma
exchange59 have been reported to benefit KD patients with
initial IVIG treatment failure. These other treatment
modalities will be discussed.
4.4. Methylprednisolone (MP) pulse therapy
At present, the usefulness of steroids in the initial treat-
ment of KD is not well established.10 Newburger et al16
reported that single-pulsed dose of intravenous methyl-
prednisolone (IVMP) compared to conventional IVIG therapy
for routine primary treatment of KD in children does not
improve treatment outcome. However, IVMP therapy seems
to benefit IVIG-resistant KD patients.60 Miura et al61
revealed the effectiveness of IVMP therapy for KD
patients that were previously unresponsive to initial IVIG
treatment. IVMP suppresses cytokine levels faster, and
subsequently, the outcomes are similar to those of IVIG
responsive patients who receive a second dose of IVIG.
Furukawa et al62 reported similar findings. IVMP seems to
have the same effect on IVIG-resistant KD patients
Fever ≥ 5 days with 2 or 3 principal criteria 
for KD 
Assess patients’ characteristics 
Consistent 
with KD  
Incomplete criteria  
for KD 
IVIG +  
2D echo 
AHA 2004 
supplemental criteria 
>38°C, 48 h 
after IVIG 
2nd dose  
IVIG  
TNF-α blockade,  
plasma exchange, 
methylprednisolone 
pulse therapy 
(No principle*) 
CRP ≥ 3 mg/dL  
and/or ESR  40 mm/h 
≥ 3 
supplemental 
criteria 
< 3 
supplemental 
criteria 
IVIG + 
2D echo
2D echo 
Echo (-), 
still fever 
Figure 1 Flow chart reference for the management of
refractory and incomplete Kawasaki disease (KD) (modified
from Newburger et al10). *There were no definite treatment
principles available for the management of KD patient with
initial IVIG resistance or unresponsiveness to other adjuvant
therapies. Second dose of IVIG (1 g/kg or 2 g/kg),10,54 meth-
ylprednisolone pulse therapy,55 tumor necrosis factor-alpha
blockade,56 cytotoxic agents (cyclophosphoamide, cyclo-
sporine A, or MTX57), plasmapheresis,58 and plasma exchange59
have been reported to benefit KD patient with initial IVIG
treatment failure. Supplemental laboratory criteria for
incomplete KD were as shown in Table 2. AHA Z American
Heart Association; CRPZ C-reactive protein; ESRZ erythrocyte
sedimentation rate; KD Z Kawasaki disease; IVIG Z
intravenous immunoglobulin; 2D echo Z two-dimensional
echocardiography; TNF-a Z tumor necrosis factor-alpha.
8 H.-C. Kuo et alcompared to an additional IVIG treatment.33 The cost-
benefit differences between IVMP and additional IVIG
should be carefully considered, taking into account
different medical conditions or health insurance policies
among countries. The first dose of IVIG is well established,
while IVMP or additional IVIG for IVIG-resistant KD patients
requires further investigation. Ogata et al33 reported that
IVMP was useful to reduce fever duration and medical costs
for KD patients with initial IVIG resistance. IVMP (n Z 13)
and additional IVIG treatment (n Z 14) were not signifi-
cantly different in terms of preventing the development of
coronary artery aneurysm. IVMP (methylprednisolone30 mg/kg per day for 3 days) or a second dose of IVIG
(2 g/kg) was prescribed to KD patients with fever and
marked inflammation (i.e., nonexudative conjunctival
injection, strawberry tongue, fissure lips, and erythema-
tous change at the BCG inoculation site) 48 hours after
initial IVIG treatment.16,33,62,63
The safety of IVMP therapy in patients with KD is
uncertain. Miura et al64 reported that IVMP (n Z 11)
incurred a higher incidence of sinus bradycardia and
hyperglycemia when compared with the additional IVIG
group (n Z 11). Hypertension did not differ significantly
between IVMP and IVIG groups. All of the adverse effects
were transient. There were no convulsions, gastrointestinal
symptoms, infections, malignant arrhythmias, or sudden
deaths in any subjects.64 Taken together, IVMP is safe for KD
patients as additional or adjuvant therapy of initial IVIG
treatment.16,65,66 After additional IVIG therapy, IVMP is
considered for KD patients with persistently poor responses
to the second IVIG treatment.54,67
4.5. Tumor necrosis factor-alpha (TNF-a) blockade
TNF-a levels are elevated in children with KD,68 and the TNF-
a (-308) genetic polymorphism is associated with KD
susceptibility, suggesting a role for TNF-a receptor blocking
in the treatment of KD, especially for those patients/cases
refractory to IVIG. The early administration of TNF-a
receptor antagonists in KD may provide effective adjunctive
therapy. Infliximab, which binds the proinflammatory cyto-
kine TNF-a, has been evaluated in several studies and shown
to have a significant effect in KD patients with IVIG
resistance.69e71 Recently, etanercept, amore suitable TNF-a
receptor blocker for children with refractory juvenile idio-
pathic arthritis,72,73was reported tobenefit the treatment of
IVIG-resistant KD as an adjuvant therapy to initial IVIG.74,75
TNF-a receptor blocker may be administered after initial
IVIG treatment failure or after a second dose of IVIG therapy.
4.6. Statins
Chronic vascular inflammation and endothelial dysfunction
persists in KD patients with CAL, even long after the acute
stage.76,77 There is currently no specific treatment for
ongoing vascular inflammation and endothelial dysfunction.
Low-dose aspirin can be prescribed until CAL normalizes,
but it does not have an effect on inflammation or endo-
thelial dysfunction. Lipid abnormalities in the acute phase
of KD, with decreased triglycerides and high-density lipo-
protein-cholesterol (HDL-C) levels have been reported in
previous studies.78,79
Statins, hydroxymethylglutaryl coenzyme A reductase
inhibitors, have been shown to reduce cholesterol levels as
well as improve surrogate markers of atherosclerosis and
cardiovascular disease.80 Huang et al81 reported that short-
term (3 months) statin treatment (simvastatin, 10 mg/day
as a single dose at bedtime) in KD patients complicated
with CAL (nZ 11) can significantly reduce total cholesterol
(TC) and low-density lipoprotein-cholesterol (LDL-C) levels,
and increase HDL-C level. Chronic vascular inflammation
is also significantly improved, as well as endothelial
dysfunction, with no adverse effects. However, long-term
Updates of Kawasaki disease 9and randomized control trials are needed before further
conclusions can be made.
Recently, Blankier et al82 also reported that atorvastatin
is able to inhibit critical steps (T cell activation and
proliferation, production of the proinflammatory cytokine
TNF-a, and up-regulation of matrix metalloproteinase-9
and an elastolytic protease) known to be important in the
development of coronary aneurysms in an animal model of
KD (murine model with injection of Lactobacillus casei cell
wall extract), suggesting that statins may have therapeutic
benefits in KD patients. Taken together, statins may be
beneficial as an adjuvant therapy in KD patients with CAL.
However, the association between dyslipidemia and
atherosclerosis in KD patients is not certain.4.7. Other treatments
Acute KD can lead to the development of large coronary
artery aneurysms that may persist for years. Abciximab,
a platelet glycoprotein IIb/IIIa receptor inhibitor, is asso-
ciated with resolution of thrombi and vascular remodeling
in adults with acute coronary syndromes. Williams et al83
reported that KD patients who were treated with abcix-
imab demonstrated greater regression in aneurysm diam-
eter at early follow-up than patients who received standard
therapy alone. McCandless et al84 also reported that
abciximab treatment might be associated with vascular
remodeling in patients with aneurysms. Abciximab seems to
benefit KD patients, especially those who developed
aneurysms.
There are still no well-defined treatments for refractory
KD. Suzuki et al85 reported that cyclosporine A (CyA)
treatment is considered safe and well-tolerated, and may
serve as a promising option for patients with refractory KD.
Hyperkalemia developed in 9/28 (32%) patients 3 to 7 days
after commencing CyA treatment. Adverse effects such as
arrhythmias should be monitored with CyA. Kuijpers et al86
described a case of mortality, and a review of the literature
showed that immunosuppressive medication such as CyA
may not influence coronary inflammation and proliferation.
Further trials are needed to clarify optimal dose, safety,
and timing of CyA treatment.
Specific changes in inflammatory markers [such as white
blood cell count, neutrophil count, CRP, IL-6, soluble IL-2
receptor (sIL-2R),87 T helper type 17/regulatory T cell
imbalance,88 and IL-1 pathway89] have been reported to
disturb immunological functions and result in KD with IVIG
resistance and CAL formation. This indicates the possible
treatment role of plasma exchange (PE) for KD with IVIG
resistance. Mori et al59 studied 46 children who had not
responded to the second IVIG treatment and subsequently
received PE and compared them with 59 children that
received a third dose of IVIG therapy. No complications
occurred with PE therapy. CAL developed in eight of the 46
children (17.3%) who received PE and in 24 of the 59 (40.7%)
who received a third course of IVIG (p < 0.001). PE is
considered safe and effective in the prevention of CAL in KD
that is refractory to IVIG therapy. PE could be performed at
an early stage, as soon as fractional increases in inflam-
matory markers are found after first or second dosage of
IVIG therapy.595. Conclusions
The incidence of KD is increasing globally,6,8,90e95 espe-
cially in Asian countries.8 Incomplete presentation of clin-
ical symptoms may complicate and delay the diagnosis of
KD, or increase the rate of CAL. Supplementary criteria for
diagnosing KD should be applied to every pediatric patient
who experiences fever for more than 5 days (with two or
three principal clinical features of KD) without a known
infection source. Due to the rate of resistance to initial IVIG
treatment, additional anti-inflammatory agents, a second
dose of IVIG, IVMP, or TNF-a receptor blockers should be
considered and administered as early as possible to
diminish inflammation, endothelial dysfunction, and CAL
formation. Because IVIG-resistant patients are at higher
risk for CAL formation, it is important to identify those who
may benefit from a more aggressive therapy. Early and
appropriate treatment of KD may decrease the life-long
sequelae of CAL in children.Acknowledgments
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